Business

Announcement on Voluntary Disclosure of Study Results of the Hematological Tumor Products, Golidocitinib Birelentinib, Being Selected To Present at the 2026 Annual Meeting of the European Hematology Association (EHA)

Announcement on Voluntary Disclosure of Study Results of the Hematological Tumor Products, Golidocitinib Birelentinib, Being Selected To Present at the 2026 Annual Meeting of the European Hematology Association (EHA)

articleDizal (jiangsu) Pharmaceutical Co. Ltd. Class AMay 13, 20263/news/announcement-on-voluntary-disclosure-of-study-results-of-the-hematological-tumor-products-golidocitinib-birelentinib-being-selected-to-present-at-the-2026-annual-meeting-of-the-european-hematology-association-eha
Announcement on Voluntary Disclosure of Study Results of the Hematological Tumor Products, Golidocitinib Birelentinib, Being Selected To Present at the 2026 Annual Meeting of the European Hematology Association (EHA)

About this update from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A

Announcement on Voluntary Disclosure of Study Results of the Hematological Tumor Products, Golidocitinib Birelentinib, Being Selected To Present at the 2026 Annual Meeting of the European Hematology Association (EHA) The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A